| Names | |
|---|---|
| Preferred IUPAC name | (2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid |
| Other names | Capoten Captoprilo Captoprilum |
| Pronunciation | /ˈkæp.tə.prɪl/ |
| Identifiers | |
| CAS Number | 62571-86-2 |
| Beilstein Reference | 3578733 |
| ChEBI | CHEBI:3380 |
| ChEMBL | CHEMBL163 |
| ChemSpider | 2157 |
| DrugBank | DB01197 |
| ECHA InfoCard | DTXSID6021057 |
| EC Number | EC 3.4.15.1 |
| Gmelin Reference | 731071 |
| KEGG | D00214 |
| MeSH | D002198 |
| PubChem CID | 44093 |
| RTECS number | TD0350000 |
| UNII | 9U1VM840SP |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID3023506 |
| Properties | |
| Chemical formula | C9H15NO3S |
| Molar mass | 217.29 g/mol |
| Appearance | White or almost white, crystalline powder. |
| Odor | Sulfide-like |
| Density | 1.338 g/cm3 |
| Solubility in water | Soluble |
| log P | 0.32 |
| Vapor pressure | 2.98E-08 mmHg |
| Acidity (pKa) | 9.8 |
| Basicity (pKb) | 7.86 |
| Magnetic susceptibility (χ) | -52.4 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.47 |
| Dipole moment | 29.1 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 267.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -491.3 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3496 kJ/mol |
| Pharmacology | |
| ATC code | C09AA01 |
| Hazards | |
| Main hazards | May cause hypotension, cough, hyperkalemia, angioedema, rash, renal impairment. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | lactose-free, gluten-free |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| Flash point | > 165°C |
| Autoignition temperature | 400°C |
| Lethal dose or concentration | LD50 (oral, rat): 12,000 mg/kg |
| LD50 (median dose) | > 2200 mg/kg (oral, rat) |
| NIOSH | MN3675000 |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Captopril: Not established |
| REL (Recommended) | 25–150 mg per day in divided doses |
| IDLH (Immediate danger) | No IDLH established. |
| Related compounds | |
| Related compounds | Enalapril Lisinopril Ramipril Benazepril Perindopril |
| Property | Technical Commentary and Manufacturer Perspective |
|---|---|
| Product Name & IUPAC Name |
Product Name: Captopril IUPAC Name: (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid As a manufacturer, clarity in naming minimizes miscommunication along regulatory and supply chains. Captopril, under its IUPAC designation, ensures proper alignment with pharmacopeial references and regulatory submissions. The preferred chemical identity, for both QC release and compliance checking, depends on contractual and regulatory context. |
| Chemical Formula |
C9H15NO3S The formula indicates the expected stoichiometry for batch yield calculations, molecular weight verification, and impurity profiling in GMP production. Lot tracking in production maintains alignment between theoretical and practical conversion rates—particularly relevant during audits and investigations into out-of-spec variations. |
| Synonyms & Trade Names |
Synonyms: 1-[(2S)-2-Methyl-3-mercaptopropanoyl]-L-proline, SQ 14225 Commercial synonymization helps to map regulatory cross-references and distributor requests. As a manufacturer, careful documentation of synonym relationships streamlines contract manufacturing, particularly for multi-source generic supply. Clear records of synonyms and registered names reduce relabeling risks, regulatory obstacles, and batch disposition disputes. |
| HS Code & Customs Classification |
HS Code: 29335995 (according to common pharmaceutical APIs under international trade classification) Customs classification drives how finished goods and key intermediates are declared for export and import. The HS code may be affected by regional interpretations or updates in international conventions, so final logistic documentation draws from the current tariff schedule of the shipping/receiving country. Any ambiguity is resolved by referencing the product’s intended end-use and individual jurisdiction rulings, with technical support provided as required during customs queries. |
In production, Captopril usually appears as a white to off-white crystalline powder. Color nuances depend on trace impurities and synthesis conditions. Bulk batches expose a characteristic sulfhydryl odor; strength varies with process residuals.
Melting and other phase transition points arise as key in QC assessment. Actual melting range varies for different grades. Density measurement factors into flow characterization for processing and formulation. Captopril’s flash point and boiling point rarely provide limiting factors during manufacture or transport since safe handling measures preclude typical combustion or distillation. End-use applications rarely expose the compound to such extremes.
Captopril’s free thiol group renders the substance particularly sensitive to oxidation. Exposure to oxidative environments or light accelerates degradation, resulting in disulfide-linked dimers or other altered products. Process controls address atmospheric oxygen and humidity to minimize such changes during manufacture and storage. Handling and packaging remain points of focused risk mitigation.
Solubility varies by temperature, medium pH, and grade. In industrial settings, water solubility remains adequate for most process and QC needs. Solubility in organic solvents factors into downstream formulation and derivatization. In production, solution preparation requires careful pH adjustment to avoid hydrolysis or oxidation.
Specification sheets distinguish between pharmaceutical, veterinary, and industrial grades. Specific assay values, impurity thresholds, and physical traits all adapt to the application. For high-purity grades, impurity levels are set according to pharmacopeia or client-specific protocols.
Dimers and oxidation products comprise the principal impurities observed. Process solvent residues, trace organic compounds, and metal content originate from raw materials, plant equipment, or handling stages. Exact impurity limits derive from product grade, regional pharmacopeial standards, and customer requirements.
Analytical methods for assay and impurity determination rely primarily on HPLC, with conditions tailored to separate captopril from known process-related impurities. IR and UV-VIS provide additional identity confirmation. Microbial contamination controls follow established protocols for pharmaceutical substances, with environmental monitoring incorporated in GMP-compliant plants.
Main starting materials include L-proline derivatives and established thioactive building blocks, sourced from vetted global suppliers with validated supply chains. Material consistency impacts final product purity profile and process reproducibility.
Production routes favor multistep synthesis with careful protection/deprotection of sensitive groups. Thiol introduction remains the defining challenge, demanding rigorous exclusion of oxidants during this step. Route selection reflects cost, yield, and impurity minimization rather than single-criterion optimization.
Key operational controls monitor pH, temperature, and reaction time, especially during critical thiolation and coupling steps. Impurity removal strategies include crystallization, activated carbon treatment, and solvent washing. Final purification is dictated by target grade, impacting recovery yield and cost.
Batch release relies on conformance to customer specifications and internal limits. All QC analyses—including impurity profiles, assay, and residual solvent content—are conducted on each lot. Release standards may vary geographically and are subject to revision for regulatory or client changes.
Captopril’s thiol group enables disulfide formation, S-alkylation, and oxidation. Reaction partners and pH dictate conversion rates and side product nature. In derivatization work, esterification or amidation of carboxyl groups proceeds under mild conditions to minimize thiol oxidation.
Oxidation and dimerization occur rapidly in open air or at elevated pH, so inert-gas blanketing and controlled temperatures dominate best practices. Strong bases or oxidants are avoided, especially during storage and post-synthesis handling.
Further chemical modification targets prodrugs or intermediates for advanced APIs. Downstream uses may leverage enantiopure or modified analogs, depending on therapeutic pathway requirements or patent landscapes.
Humidity and light exposure accelerate Captopril degradation. Factories and warehouses indicate storage in cool, dry areas, with tightly sealed, light-protective containers. Storage conditions are calibrated against the most stringent expected customer specification.
Containers are chemically inert (usually HDPE or glass with tamper-evident closures), minimizing risk of interaction with sensitive functional groups. Metal contact surfaces are avoided downstream of synthesis to reduce contamination risk.
Shelf life depends on grade, packaging, and storage exposure profile. Degradation typically presents as odor increase, discoloration, or formation of insoluble particulates. Stability monitoring includes regular re-sampling and retesting of retained batches.
Hazard classification reflects the presence of a reactive thiol group, with irritant potential and sensitization risk for industrial handlers. GHS pictograms and risk phrases conform to regulatory updates and substance handling experience.
Factory workflows require avoidance of inhalation and skin contact, given known occupational exposure risks. Automated handling and dust suppression are standard in primary material transfer zones. Eye and respiratory protection are standard for personnel during open processing.
Toxicological profile is referenced from established monographs for active pharmaceutical ingredients. Direct handling precautions stem from known skin and mucosal irritant potential at concentrated levels.
Internal exposure guidelines adhere to regionally established worker protection limits, with air quality and surface monitoring forming part of GMP and EHS controls. Containment, PPE deployment, and training address risks tied to fineness of bulk material and reactivity of free thiol.
Production output for captopril depends primarily on the route employed and the scale of unit operations. Manufacturing via the thiol-alkylation pathway allows flexible batch sizes, but intermediate availability and purification bottlenecks may limit surge capacity. For global API clients, campaign-based production planning supports bulk requirements, but rapid scale-up typically depends on advance forecast alignment. Finished API is typically released after meeting internal analytical and impurity specifications, which are batch-specific and reflect both customer order volume and intended market registration.
Lead time for captopril is controlled by raw material procurement and in-process validation steps. Larger commercial orders, usually above five-digit kg annual volumes, require contract-based scheduling, while spot orders see longer lead times if outside campaign windows. For smaller orders or less common packaging, MOQs reflect not just production economics but also regulatory batch-release costs and packaging component availability. MOQ is negotiated based on destination market, packaging type, and analytical documentation requirements.
Standard packaging for captopril API balances material protection and logistics efficiency. For regulated markets, double-layer polyethylene liners within HDPE drums offer moisture and oxidation control. Custom packaging, such as intermediate bulk containers or smaller dose packs, may be available for EU or US clients subject to validation of barrier integrity and traceability. All packaging configurations require cleaning validation and batch traceability documentation, with release conditioned on meeting both transportation compatibility and pharmacopoeia requirements.
Shipping terms are usually negotiated by INCOTERMS, with EXW, FOB, and CIF as most regularly adopted. Temperature and humidity control is specified for ocean transit to high-risk zones. Payment terms for repeat customers may include open account or documentary LC, depending on volume and credit profile, whereas prepaid or confirmed LC is the control choice for first transactions or higher-risk jurisdictions. All shipments undergo pre-dispatch certificate of analysis and regulatory compliance review.
Raw material inputs dominate variable costs, with highest sensitivity tied to the thiol donor source and main intermediate cost. Volatility in the bulk chemical market, especially for protected amines and thiol compounds, directly reflects in offered API pricing. Energy and solvent consumption per batch alters with process intensity and batch size, causing periodic shifts in variable cost structure.
Captopril’s raw material costs fluctuate mainly from upstream supply chain disruption, currency shifts (notably USD and CNY), energy pricing, and compliance-driven changes in permissible solvents or reagents. Environmental controls and increasing regulatory pressure over waste disposal in major manufacturing hubs such as China and India often result in step-change adjustments to production cost.
Finished API prices vary more for certified GMP versus technical or non-regulated grades. GMP-grade involves greater documentation, released stability data, and regulatory audit support. Purity specification (e.g., ≥99% by HPLC vs. broader cutoffs) and impurity profile (specified per ICH Q3A/B standards) factor into batch price. Packaging that meets EU/US cGMP seal or custom serialization adds surcharge. Final quote reflects a matrix of these grade, purity, and packaging requirements, dictated by regulatory expectation and downstream formulation stability.
Worldwide demand remains stable from historic hypertension therapy prescription patterns. API manufacturing hub location affects logistics and supply resilience: consolidation to Asia provides cost advantage, but exposes buyers to risk from single-source disruptions. Demand from US and EU is shaped by formulary penetration, while India increasingly sources for both domestic formulation and export market.
US and EU buyers tend to secure supply through multi-year agreements with preferred manufacturers, focusing on compliance and batch traceability. Japanese buyers request additional documentation for raw material genealogy and often require in-country QC retesting. Indian and Chinese formulators are more price sensitive and responsive to spot market movements, using high-volume orders to leverage scale discounts. Regional regulatory requirements on impurities and packaging stipulate unique batch documentation and flow-down compliance for each economy.
Forecasts for captopril API through 2026 point to cost-driven price increases if energy, labor, or regulatory compliance costs rise further in primary manufacturing regions. Stable pharmaceutical demand means most buyers will see modest, index-driven adjustments, unless another regional compliance overhaul or supply shock occurs. Pricing structure will remain tiered by grade and compliance documentation. No significant global oversupply is expected barring major generic market withdrawal or large-scale regional capacity addition.
Market assessments come from aggregating global export-import declarations, customer order records, and third-party contract comparison where permitted. Price trend forecasting uses indexed raw material contract data, published regulatory filings, macroeconomic trends, and input from multi-regional production teams.
Ongoing production shifts in China and India, sometimes in response to environmental enforcement actions or third-party regulatory inspections, have affected raw material pricing and short-term availability. Multinational pharmaceutical buyers increase pressure for traceability and ESG-compliant production across supplier tiers.
Recent updates to pharmacopeial standards for captopril, particularly impurity threshold levels and control for isomeric forms, require ongoing review of both in-process and final-release QC. Regulatory authorities in US and EU have stepped up scrutiny of solvent residues, triggering additional validation requirements and routine site inspections.
Manufacturers respond by increasing batch traceability, expanding post-release stability monitoring, and increasing dual-sourcing of vulnerable raw material intermediates. Batch testing scope for registration markets broadens to include full compendial compliance for impurities and residual solvents. Where regulatory shifts impose new requirements, process revalidation and updated compliance filing support continued access to key regulated markets.
Captopril production primarily supports the pharmaceutical sector, with the compound serving as an active pharmaceutical ingredient (API) in antihypertensive medications. Secondary applications include use in research and analytical laboratories, and small-scale development for controlled drug release studies. Across these environments, grade selection dictates downstream processing, regulatory pathway, and risk management requirements.
| Grade | Typical Application | Critical Selection Factors |
|---|---|---|
| API (Pharma) Grade | Final formulation for oral antihypertensive drugs (tablets, suspensions) | Complies with relevant pharmacopeial monographs; handles with strict impurity and residual solvent requirements, tight batch-to-batch consistency, full traceability. |
| Research Grade | Lab-scale synthesis, R&D analytics | Focus falls on typical purity sufficient for protocol development; not suitable for clinical or commercial drug formulation. |
| Custom / Intermediate Grade | Contract manufacturing, intermediates for combination therapies, non-human applications | Specification to be defined based on end-user process, can include custom impurity profile requests or specialized controls for particular process needs. |
| Parameter | Industry Standard Expectation | Grade Dependence | Application Sensitivity |
|---|---|---|---|
| Assay (Captopril Content) | Pharma grade typically supports narrow assay ranges; research grade accepts broader range. | Varies by pharmacopeia or customer spec. | Critical in API applications; leeway for non-pharma research use. |
| Impurity Profile | Controlled through validated purification; residual solvents and process-related impurities monitored closely for pharma grades. | Stricter for API; flexible for research or industrial intermediates. | Central to release for direct medication; less stringent for method development. |
| Particle Size Distribution | Defined for tablet production to ensure content uniformity and compressibility. | Typically specified for finished dosage API supply; less-controlled for bulk or non-final forms. | Significant in formulation scale-up; minor in analytical research. |
| Moisture Content | Controlled to support shelf life and downstream stability. | Release criteria dependent on grade, particularly for hygroscopic sensitivity in finished formulation APIs. | Stability risk for storage, especially in high-humidity regions or long shipping routes. |
Start by establishing the end use, whether for human pharmaceutical production, R&D, or as a process intermediate. API and research applications require different risk controls, impurity tolerance, and batch documentation.
Regulatory status influences grade selection. Commercial API supply in regulated markets uses grades meeting local pharmacopoeial requirements (USP, EP, JP, etc.), governed by Good Manufacturing Practices. Non-GMP or research-only applications often allow more flexibility, but the user bears responsibility for risk management.
Pharmaceutical formulations require a fully traceable compound with qualified impurity spectrum and justification for residual solvents. Research users may tolerate higher variability in these parameters if human or veterinary use is not involved.
API grades, with extensive quality management, incur higher manufacturing and documentation costs. For pilot, scale-up, or lab demand, multi-kilo or sub-kilo supply may be sourced at lower specification levels, balancing need and budget. Manufacturing volume impacts process route (batch vs. continuous), which further impacts impurity trends and reprocessing logic.
Laboratory analysis of a representative sample provides direct evidence of lot-to-lot consistency and confirms suitability for downstream application. Validation batches often expose unforeseen formulation or analytical challenges tied to grade-specific parameters such as particle size, solubility, or reactivity trace ions.
Sourcing follows strict supplier qualification and monitoring. The pathway to bulk synthesis uses materials with known impurity profiles, minimizing introduction of halogenated species or heavy metals, since residuals impact release suitability and regulatory compliance.
Route choice, whether through thiol-ene click chemistry or via routes starting from L-proline, stems from balance of yield, cost, and generation of process-specific byproducts. Certain pathways minimize formation of process-specific impurities (e.g., S-oxidized derivatives), relevant for later purification.
Critical points include temperature and pH control during condensation, and redox stability through crystallization steps. In-process controls spot-check intermediate and final impurity profiles, with rapid adjustments to quench or isolate if detrimental species rise above control limits.
Depending on grade, recrystallization and solvent washes, coupled with advanced chromatography, address impurity and solvent residue. For pharma grade, broad-spectrum impurity mitigation and validation of removal effectiveness align with regulatory expectations; for research grade, selective removal balances effort and intended use.
Stringent API grades carry extensive batch documentation, chain-of-custody, and harmonized analytical release. Batch reconciliation, yield trending, and statistical process control feed into continuous improvement. For non-API supply, batch records are retained but documentation may fit customer agreements rather than regulatory templates.
Release to customer follows internal technical specifications, set cooperatively with the end user's requirements, including reference standard matching for API, impurity fingerprinting, and relevant stability or process validation. The final release standard reflects both in-house results and, if necessary, third-party confirmatory analysis.
In industrial captopril production, traceability starts with establishing clear quality system boundaries and documented accountability from raw material sourcing to final release. The manufacturing facility operates under a formal quality management system audited to internationally recognized standards such as ISO 9001 for quality management. This base framework integrates risk-based process controls and routine quality reviews that prioritize consistency, compliance, and root-cause-driven deviation handling.
Routine internal audits and corrective action programs track process variation and direct improvement projects to verified risk zones, such as critical control points in synthesis or packaging lines. Supplier qualification procedures and incoming material verification are tailored to the compound’s sensitivity, especially in reducing impurities like sulfoxide-related byproducts. Facility-wide batch records, environmental monitoring logs, and calibration traceability for analytical equipment form a core part of the documented system supplied with regulatory submissions.
Depending on the targeted market, specific product certifications such as GMP (Good Manufacturing Practice) for pharmaceutical APIs are available for captopril. These certifications stem from comprehensive audits that examine material tracking, cross-contamination prevention, and evidence of validated cleaning protocols in shared equipment scenarios. Where market access demands it, DMF (Drug Master File) registrations or CEP (Certificate of Suitability, EDQM) documentation are maintained and updated in line with lifecycle changes, formulation requirements, and regulatory expectations.
Release criteria for captopril lots are set according to both global pharmacopeia monographs (e.g., USP, EP, JP) and customer-specific requirements, with final COA (Certificate of Analysis) incorporating validated analytical results. Specifications may vary by grade—for example, excipient use in formulation versus direct tableting API standards—so availability of documentation for each grade is advised during initial qualification.
Each supply lot is accompanied by a full release dossier on request: batch COA summarizing routine QC parameters, process deviation summaries if applicable, and method validation packages for key tests. Impurity profiles, stability protocols, and supplier statements on genotoxic impurity risk are available upon justified request and will be covered in technical transfer discussions.
For contract partners or under audit, comprehensive traceability documentation is accessible, typically including production flow charts, cleaning validation summaries, raw material qualification data, and critical process control point logs. For recurring clients, reports supporting environmental and occupational risk assessment—such as solvent loss balances and primary containment integrity summaries—can be provided as part of customer-specific quality agreements.
Facility production lines for captopril are structured around multi-purpose reactor suites with grade and batch size flexibility to support both large-volume contracts and custom batch requirements. Process scheduling leverages validated campaign-switch cleaning protocols and inventory management systems that accommodate fluctuations in market demand and regulatory shipment windows.
For customers with project-based forecasts or unpredictable demand cycles, flexible call-off orders, just-in-time delivery scheduling, and buffer stock arrangements can be configured upon agreement. Process cost drivers, such as precursor cost swings or yield variation linked to scale, are transparently explained in framework agreement discussions.
Typical manufacturing assets reserved for captopril production include high-throughput reactors, down-flow workup suites, and in-line analytical verification units to ensure batch homogeneity and impurity minimization. To mitigate single-point failure risk, dual supply stream models and backup policy for critical intermediates are in effect. For grade-dependent requirements, dedicated production windows for high-purity API and technical grades reinforce continuity in complex supply chains.
Batch consistency is managed by integrating automated data management in critical quality attribute monitoring and lot genealogy systems, which support both internal QA and external regulatory audits.
Sample requests for new formulation development or plant qualification are handled through a technical pre-qualification form, prioritizing traceable small-batch sampling with concurrent documentation on analytical profile, origin, and batch-specific process notes. For atypical applications or customer-specific test requirements, flexible mini-batch production is available with joint test protocol development between the QA team and customer’s technical representatives.
Sample shipment aligns with transport guidelines for sensitive bulk pharmaceuticals, using validated containment and regulatory declarations.
Business cooperation can extend beyond consignments to technical partnership, such as co-development on new synthetic routes for custom impurity thresholds or joint troubleshooting for downstream formulation issues. Customers may propose adaptive ordering, shared risk on capacity scale-up, or process revalidation triggers tied to their own regulatory milestones.
Where forecast stability is limited, options for rolling contracts, quarterly lot reservation, or expedited change notification updates can be discussed. For clients implementing strict change control or custom release testing, process documentation access and priority audit scheduling are incorporated into supply agreements to prevent disruptions.
Process development receives ongoing investment as manufacturers face the need to stabilize impurity profiles and manage cost pressures for Captopril across various grades. Selection of synthetic routes, from classical oxidation-reduction pathways to biocatalytic steps, reflects both regulatory expectations and local process economics. For high-purity pharmaceutical applications, focus centers on reducing key impurities such as diketopiperazine and disulfide by-products, which are closely tracked during scale-up and batch release. End-users increasingly request data packages linking in-process control to final impurity limits, especially for export to markets with tight pharmacopoeial alignment.
Expansion into fixed-dose combinations and pediatric dosage forms pushes R&D beyond routine tablet production. Application teams in our sector have seen greater demand for particle size control, flow aid compatibility, and rapid-dissolving forms suitable for non-solid oral administration. Technical requests now frequently involve polymorphic form characterization, optimization for specific granulation protocols, and stability in multi-component blends.
Persistent issues involve odor management during synthesis and handling, owing to Captopril’s sulfhydryl group. Controlling atmospheric exposure, especially under humid conditions, impacts downstream tablet odor and patient acceptability. Manufacturers have introduced inert gas blanketing and closed-system handling to limit oxidation and volatile sulfur compound formation. Process improvements around solvent recovery, waste reduction, and energy input optimize cost structures and address tightening site-level emissions controls. Continuous flow processes, though less common, are being explored to decrease batch-to-batch variability, particularly for export-destined pharmaceutical grade lots.
Downstream demand for Captopril tracks the treatment of hypertension and heart failure, with slight regional shifts as newer therapies encroach on originator use in certain markets. Generic supply contracts, multinational procurement, and penetration into emerging economies drive moderate volume growth. Price pressure remains pronounced as active ingredient commoditization intensifies, especially for generics subject to routine tenders or price controls. Manufacturers must weigh cost-containment with traceability and compliance demands as global regulatory oversight increases.
Technical teams see gradual advances in in-line analytics and automated impurity monitoring per batch. Laboratories utilize more robust chromatographic techniques for both process and release testing, reflecting customer demand for deeper visibility on impurity fate. Investment in automation and digital twin modeling supports greater reproducibility and tighter process controls. Customer specification harmonization may push toward regional process customization or supply-chain modularity, forcing manufacturing sites to maintain flexible production lines and rapid changeover capability.
Raw material teams prioritize sourcing with lower embodied energy and reduced hazardous waste output. Selection of greener oxidants and solvents, along with solvent recovery infrastructure, aligns with both regulatory and customer-driven sustainability agendas. Ongoing projects focus on catalyst recyclability, process water reuse, and emissions reduction not only to meet compliance but also to address increasing customer requirements for environmental disclosure. Process adjustments may be adopted to allow for less resource-intensive production routes if they meet critical impurity and performance targets.
End-users rely on direct manufacturer technical assistance for trouble-shooting during product scale-up, especially at the formulation and tableting stages. Questions about polymorph stability, impurity behavior under customer-specific storage conditions, and compatibility with auxiliary excipients arise frequently. The technical department maintains a file of past query resolutions and root cause analyses, enabling structured guidance for new inquiries.
Our quality and process engineers review end-user processing conditions upon request and make recommendations ranging from dissolution optimization to odor mitigation, tailored to customer formulation lines. Knowledge of process history—batch records, impurity trend charts, moisture sensitivity studies—enables technical teams to offer validated solutions. Adjustments in particle size distribution or residue limit tolerances are considered in collaboration with customer quality personnel to balance process robustness with final product performance.
We commit to investigating quality concerns down to lot traceability and raw material lineage. Manufacturers maintain samples for retesting, permit customer audits, and provide change notifications on starting material, route, or specification changes. The after-sales team logs complaint trends and shares corrective action findings as part of ongoing customer quality management. Detailed batch release criteria and internal review records are available for reference according to end-use or regulatory filing needs.
Captopril stands as a widely used ACE inhibitor essential to both pharmaceutical formulation and R&D applications across several regions. Direct from our manufacturing facility, we manage the full process from chemical synthesis to finished powder and granule forms. Every batch relies on tightly defined starting materials, proven synthetic pathways, and environmental controls. Our operation meets current GMP standards, with all handling, drying, and milling steps managed by in-house teams using validated protocols and automated monitoring to reduce deviation.
Manufacturers of finished pharmaceuticals look for reliable, high-purity captopril to produce consistent antihypertensive medications and fixed-dose combinations. Our product supports both large-scale oral dosage production and smaller pilot plant requirements. In chemical research and analytical development, labs use our captopril as a trusted reference and for comparative testing.
Raw material sourcing and incoming QC follow strictly written procedures. Analysts handle in-process checks including moisture, assay, and impurity tracking at each stage. Final product undergoes full analytical testing in our on-site QC lab, using methods including HPLC and FTIR, following validated monograph standards. Retained samples from every lot support traceability and after-market investigations. Routinely scheduled calibrations and ongoing improvements support both regulatory compliance and actual field performance.
We operate dedicated filling and packing lines designed for pharmaceutical actives. Standard drum sizes range from 10 kg to 50 kg in double-lined, sealed PE bags contained in rigid drums. For high-throughput users, custom packaging can be executed to align with automated feeder systems or intermediate storage zones. Each drum leaves the plant with clear labelling, including batch information and safety management instructions. Logistic teams coordinate rapid, customs-ready dispatch, using validated partners for air, sea, and land shipments.
Technical and supply specialists with on-floor production background advise on integrating captopril into solid dose lines or tailored R&D workflows. Support extends to trouble-shooting process compatibility, scaling issues, and compliance documentation. Our teams maintain ongoing relationships with industrial development teams, streamlining the knowledge transfer over the entire lifespan of a supply agreement.
Direct procurers in pharmaceutical manufacturing benefit from batch traceability, specification control, and predictable scheduling. Distributors working with us gain secure, planned allocation from our regular output, reducing supply interruption risks. For procurement leaders, supply chain confidence rests on year-over-year production data, local regulatory certifications, and documented audit trails. By holding every step of captopril’s lifecycle "in plant," from synthesis to shipment, we support reliable business outcomes, not just technical compliance.
| Feature | Benefit for Industrial Customers |
|---|---|
| Integrated production | Improved traceability and batch consistency |
| On-site QC laboratory | Faster turnaround and assured release documentation |
| Professional technical support | Direct advice on plant integration and process solutions |
| Packing and logistics management | Secure shipment and flexibility in delivery scale |
By keeping every production, testing, and supply function under one operation, we set clear expectations for industrial buyers, regulatory authorities, and supply partners. Decades of practical experience in chemical manufacturing shape our response to evolving business needs and compliance environments.
Producing Captopril tablets starts with a firm grasp of the chemistry behind its pharmacological impact. As a direct manufacturer, we emphasize the science. Captopril belongs to the ACE inhibitor class. This means it works by blocking the angiotensin-converting enzyme (ACE), which is necessary for the conversion of angiotensin I to angiotensin II—a potent vasoconstrictor. By disrupting this process, Captopril reduces vascular resistance, eases blood pressure, and relieves cardiac workload. Beyond blood pressure, we recognize its role in managing heart failure and protecting kidney function in some chronic conditions. Every batch we manufacture reflects careful adherence to these scientific facts, since the therapeutic value hinges on enzymatic inhibition matched to precise dosing and release profiles.
Our technical team crafts Captopril tablets using a formula honed for stability, bioavailability, and ease of use. The core tablet contains more than the active compound. Through years of in-house R&D and feedback from pharmacologists, we’ve selected excipients based on their interaction with both the API and the patient’s needs. Stability is a particular concern—Captopril’s sulfhydryl group can oxidize, so every excipient must support a longer shelf life in varying conditions.
For direct compression, we incorporate microcrystalline cellulose to form the backbone of the tablet matrix. It promotes robust mechanical strength and reliable disintegration profiles. Lactose often complements as a filler, ensuring the final tablet hits the right weight and density for automated tablet presses. To facilitate fast yet controlled breakdown in the digestive tract, we leverage disintegrants like croscarmellose sodium. Each element is chosen from proven suppliers and undergoes strict incoming quality checks in our facility.
Flowability and compressibility differ from batch to batch. Magnesium stearate earns a spot as a lubricant, mitigating sticking and ejection problems during high-speed compression. This excipient enables our equipment to maintain consistent output without downtime, supporting large order commitments without compromising quality. Our process leaves no residues above accepted pharmaceutical thresholds, verified by in-house HPLC analysis for every lot we release.
Captopril’s bitter taste and potential odor sometimes demand a film-coating system. We often deploy a thin layer of hydroxypropyl methylcellulose-based film with titanium dioxide for protection and patient acceptance. This coating also shields the API from light and air, further lengthening shelf stability before the product reaches the market. Our coating process employs minimal aqueous solvents and has been refined to avoid excess moisture exposure to the hygroscopic API.
We maintain each production line under full GMP standards, monitored by our QA and QC teams from blending to finished product. Incoming raw materials and each finished batch undergo comprehensive analytical testing. Moisture-sensitive products like Captopril require controlled humidity in blending and compression rooms, all managed using advanced HVAC and dehumidification systems in the facility. We address cross-contamination and product integrity with segregated zones and validated cleansing protocols.
Our technical documentation includes full traceability for every lot of excipient, and we update formulations only after thorough process validation and customer consultation. On request, we provide detailed specifications, including excipient grades, sourcing, and potential alternatives based on export and regulatory requirements.
Reliable delivery of Captopril tablets means tackling both chemistry and practical handling. Our experience underscores that consistent quality begins long before tablets reach the market, rooted in technical understanding and investment in each raw material and process step.
Producing Captopril in bulk has long been a core part of our operation. Our factory runs multi-ton production suites year-round, giving us flexibility in scaling capacity and managing clients’ requirements with predictable schedules and volume guarantees. Large-scale manufacturing brings specialist challenges, but experience demonstrates that efficiency grows when minimum order sizes and scheduling remain clear and consistent.
Bulk customers in the pharmaceutical sector usually require significant batch sizes to support both finished drug formulation and supply chain reliability. For Captopril, our minimum lot for bulk orders starts at 25 kilograms. This quantity reflects both processing efficiency and the threshold at which cost control and logistics remain economic all the way from synthesis through to export packaging.
Moving below this threshold often introduces waste in both production and compliance steps, especially in facilities built for industrial-scale output. Coordinating multiple customer lots within a batch can sometimes reduce costs, but small-lot orders tend to drive both price and delivery unpredictably. We focus on serving manufacturers and formulators planning continued or recurring procurement. Orders well above the minimum—across hundreds of kilograms—are routine and usually bring more flexibility on terms.
Reliable lead times begin with transparent scheduling. For Captopril, we maintain rolling stock based on forecasted demand, but sizable contracts or first-time partnerships often require coordination with our master production plan. On average, the lead time for fresh production runs is four to six weeks from the order confirmation date. Repeat clients drawing from standing agreements or reserve lots may experience shorter cycles.
A number of factors in chemical synthesis affect these timelines. Raw material procurement, quality control sampling, and documentation for compliance each take time, and we never skip steps to speed up delivery. Sometimes, spikes in global demand or unexpected regulatory review periods cause temporary delays. Our logistics team works closely with partners when delivery time is critical. Air and sea shipment options, batch consolidation, and finished-goods inventory management support customers who need consistent delivery intervals.
Each shipment of Captopril leaves the factory with batch traceability, full documentation, and a certificate of analysis. Most clients opt for fiber drums or high-barrier lined bags with net weights of 25 kg, but we can tailor packaging for unique handling or processing systems. Our quality assurance crew provides continuous monitoring for residue solvent levels, particle profile, and moisture parameters since these directly impact further formulation or tableting.
Long-term clients need stable supply arrangements and direct access to a manufacturer whose technical staff stands behind each batch. Our team can support material qualification, process tech transfer, and on-site audits as needed. Investing in process improvement also helps us shave days off future lead times and lower overall costs through yield improvements and raw material agility.
Every bulk order connects you straight to our production floor. Clients do not deal with layers of intermediaries, which means clearer communication, tighter IP control, and rapid response to changing needs, whether it is a new regulatory filing or an unexpected spike in demand.
Operating a pharmaceutical facility means regulatory requirements shape every step on the production floor. For us, cGMP is more than an acronym. Our captopril manufacturing adheres to guidelines set forth by international authorities such as the FDA and EMA, which shape the design of both our quality management system and day-to-day process controls. Auditors walk our lines and review our documentation. We train every staff member on hygiene programs and process integrity, reinforcing a mindset where cross-contamination and deviation are simply unacceptable.
Batch records and equipment logs receive constant attention, and each lot of captopril must meet stringent release criteria based on validated analytical methods. Any deviation gets a root cause investigation with corrective action. We maintain exacting records for traceability from raw material through finished goods to final distribution. For years, these systems have served us and our clients well, not just to satisfy inspections but to safeguard patient health.
Clear storage and shipping protocols make the difference between a compliant supply chain and one that exposes risk. Our captopril leaves the plant only after final release and stability data checks. We specify storage below 25°C, protected from moisture and light, based on established long-term and accelerated stability studies. These requirements drive our choice of packaging materials and handling procedures, right down to labeling and palletizing for international transit.
We spent the necessary effort validating every step, from temperature mapping of our warehouses to the use of climate-controlled containers when shipments cross borders or face unpredictable customs queues. Logistics is not an afterthought. Our team works closely with freight partners to ensure chain-of-custody, monitoring for temperature excursions during transit and storage disruptions at any leg of the journey. Each customer receives shipping documentation, storage guidance, and the support of our regulatory team to answer compliance questions unique to their region.
We produce active pharmaceutical ingredients that become life-saving medications. Any break in the chain — from raw material qualification, in-process monitoring, or shipment handling — can compromise not just regulatory standing, but lives. Agencies expect complete transparency, and anything less than absolute clarity invites recall or loss of trust.
Clients bring questions shaped by regional health authorities, and our technical staff provides full documentation — not just certificates of analysis, but process validation summaries, cleaning validations, elemental impurity data, and evidence of cold-chain compliance when required. We stay up to speed as pharmacopoeias and import rules update, so nothing escapes our compliance radar.
Years in manufacturing have shown that gaps, ambiguities, or shortcuts cost far more than the effort invested in a robust, repeatable, and auditable process. This is how we sustain long-term partnerships and keep our product trusted by global pharmaceutical companies.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
